April 27, 2024

Sen. Bernie Sanders (I-VT) is call­ing on glob­al phar­ma­ceu­ti­cal lead­ers to get be­hind pro­pos­als laid out in a World Health Or­ga­ni­za­tion-led glob­al pan­dem­ic pre­pared­ness agree­ment

Ipsen’s new spon­sored Tik­Tok fea­tures the pop­u­lar “Of course” trend and two so­cial in­flu­encers, but with a rare dis­ease twist. The short video shows two

Bris­tol My­ers Squibb is clos­ing a cell ther­a­py R&D site in Cal­i­for­nia as the com­pa­ny im­ple­ments a $1.5 bil­lion cost-cut­ting pro­gram that was an­nounced this

Ab­b­Vie’s ef­fort to pro­tect Hu­mi­ra’s mar­ket share is get­ting ex­pen­sive. On Fri­day, the com­pa­ny an­nounced a 40% de­cline in the megablock­buster drug’s US sales for

“We’re in a frothy time,” ac­knowl­edges Alexan­dra Sny­der, the head of R&D at Gen­er­ate:Bio­med­i­cines. Gen­er­ate is one of the AI-dri­ven biotechs that make up a

Plus, news about Biodexa Phar­ma­ceu­ti­cals: RevOp­sis Ther­a­peu­tics se­cures $16.5M seed round: The San Car­los, CA-based biotech will use the funds to com­plete IND-en­abling stud­ies for

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)  Cigna’s health ser­vices arm Ever­north said on

Pfiz­er an­nounced Fri­day morn­ing that the FDA ap­proved its gene ther­a­py for the rare ge­net­ic bleed­ing dis­or­der he­mo­phil­ia B. The one-time treat­ment, known gener­i­cal­ly as

→ UCB is shak­ing up its lead­er­ship team “to bet­ter align with its com­mit­ment to growth and in­no­va­tion, and to bet­ter ad­dress the dy­nam­ic ex­ter­nal